Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 2, 2008 - Issue 4
Submit an article Journal homepage
134
Views
30
CrossRef citations to date
0
Altmetric
Review

Assessing liver fibrosis

Laurent Castera Service d’Hépato–Gastroentérologie, CHU Bordeaux, Hôpital Haut Lévôque, Avenue Magellan, 33604 Pessac, France. [email protected]
Pages 541-552 | Published online: 10 Jan 2014

  • Bravo AA, Sheth SG, Chopra S. Liver biopsy. N. Engl. J. Med.344(7), 495–500 (2001).
  • EASL International Consensus Conference on Hepatitis C. Paris, 26–27 February 1999. Consensus Statement. J. Hepatol.31(Suppl. 1), 3–8 (1999).
  • NIH Consensus Statement on Management of Hepatitis C: 2002. Hepatology36(3), S3–S20 (2002).
  • Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology1(5), 431–435 (1981).
  • Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J. Hepatol.22(6), 696–699 (1995).
  • Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology20(1 Pt 1), 15–20 (1994).
  • Hubscher SG. Histological grading and staging in chronic hepatitis: clinical applications and problems. J. Hepatol.29(6), 1015–1022 (1998).
  • Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology32(3), 477–481 (2000).
  • Castera L, Negre I, Samii K, Buffet C. Pain experienced during percutaneous liver biopsy. Hepatology30(6), 1529–1530 (1999).
  • Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J. Hepatol.2(2), 165–173 (1986).
  • Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology38, 1449–1457 (2003).
  • Maharaj B, Maharaj RJ, Leary WP et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet1(8480), 523–525 (1986).
  • Poniachik J, Bernstein DE, Reddy KR et al. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest. Endosc.43(6), 568–571 (1996).
  • Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am. J. Gastroenterol.97(10), 2614–2618 (2002).
  • Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand. J. Gastroenterol38(4), 427–432 (2003).
  • Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J. Hepatol.39(2), 239–244 (2003).
  • Rousselet MC, Michalak S, Dupre F et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology41(2), 257–264 (2005).
  • Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut55(4), 569–578 (2006).
  • Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin. Chem.42(4), 558–563 (1996).
  • McHutchison JG, Blatt LM, de Medina M et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J. Gastroenterol. Hepatol.15(8), 945–951 (2000).
  • Halfon P, Bourliere M, Penaranda G et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp. Hepatol.4, 6 (2005).
  • Montazeri G, Estakhri A, Mohamadnejad M et al. Serum hyaluronate as a non-invasive marker of hepatic fibrosis and inflammation in HBeAg-negative chronic hepatitis B. BMC Gastroenterol.5, 32 (2005).
  • Naveau S, Raynard B, Ratziu V et al. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin. Gastroenterol. Hepatol.3(2), 167–174 (2005).
  • Pares A, Deulofeu R, Gimenez A et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology24(6), 1399–1403 (1996).
  • Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int.25(4), 779–786 (2005).
  • Walsh KM, Fletcher A, MacSween RN, Morris AJ. Basement membrane peptides as markers of liver disease in chronic hepatitis C. J. Hepatol.32(2), 325–330 (2000).
  • Wong VS, Hughes V, Trull A, Wight DG, Petrik J, Alexander GJ. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J. Viral. Hepat.5(3), 187–192 (1998).
  • Pilette C, Rousselet MC, Bedossa P et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J. Hepatol.28(3), 439–446 (1998).
  • Oberti F, Valsesia E, Pilette C et al. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology113(5), 1609–1616 (1997).
  • Castera L, Hartmann DJ, Chapel F et al. Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J. Hepatol.32(3), 412–418 (2000).
  • Johansen JS, Christoffersen P, Moller S et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J. Hepatol.32(6), 911–920 (2000).
  • Tran A, Benzaken S, Saint-Paul MC et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur. J. Gastroenterol. Hepatol.12(9), 989–993 (2000).
  • Saitou Y, Shiraki K, Yamanaka Y et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J. Gastroenterol.11(4), 476–481 (2005).
  • Murawaki Y, Koda M, Okamoto K, Mimura K, Kawasaki H. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J. Gastroenterol. Hepatol.16(7), 777–781 (2001).
  • Murawaki Y, Ikuta Y, Idobe Y, Kawasaki H. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J. Gastroenterol. Hepatol.14(2), 138–145 (1999).
  • Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin. Chim. Acta316(1–2), 71–81 (2002).
  • Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am. J. Gastroenterol.96(11), 3142–3146 (2001).
  • Imperiale TF, Said AT, Cummings OW, Born LJ. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am. J. Gastroenterol.95(9), 2328–2332 (2000).
  • Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J. Gastroenterol. Hepatol.15(4), 386–390 (2000).
  • Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am. J. Gastroenterol.93(1), 44–48 (1998).
  • Lackner C, Struber G, Liegl B et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology41(6), 1376–1382 (2005).
  • Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am. J. Gastroenterol.99(6), 1160–1174 (2004).
  • Castera L, Pawlotsky JM. Noninvasive diagnosis of liver fibrosis in patients with chronic hepatitis C. Med. Gen. Med.7(4), 39 (2005).
  • Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J. Gastroenterol.12(23), 3682–3694 (2006).
  • Pinzani M, Vizzutti F, Arena U, Marra F. Technology insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat. Clin. Pract. Gastroenterol. Hepatol.5(2), 95–106 (2008).
  • Mehta P, Ploutz-Snyder R, Nandi J, Rawlins SR, Sanderson SO, Levine RA. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am. J. Gastroenterol.103(4), 928–936 (2008).
  • Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet357(9262), 1069–1075 (2001).
  • Poynard T, Imbert-Bismut F, Munteanu M et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp. Hepatol.3(1), 8 (2004).
  • Rossi E, Adams L, Prins A et al. Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin. Chem.49(3), 450–454 (2003).
  • Castera L, Vergniol J, Foucher J et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology128(2), 343–350 (2005).
  • Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med.10(4), 429–434 (2004).
  • Cales P, Oberti F, Michalak S et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology40(6), 1373–1381 (2005).
  • Halfon P, Bacq Y, De Muret A et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J. Hepatol.46(3), 395–402 (2007).
  • Halfon P, Bourliere M, Deydier R et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am. J. Gastroenterol.101(3), 547–555 (2006).
  • Leroy V, Hilleret MN, Sturm N et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J. Hepatol.46(5), 775–782 (2007).
  • Myers RP, Tainturier MH, Ratziu V et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J. Hepatol.39(2), 222–230 (2003).
  • Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J. Gastroenterol.13(4), 525–531 (2007).
  • Poynard T, Zoulim F, Ratziu V et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am. J. Gastroenterol.100(9), 1970–1980 (2005).
  • Myers RP, Benhamou Y, Imbert-Bismut F et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS17(5), 721–725 (2003).
  • Ratziu V, Massard J, Charlotte F et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol.6, 6 (2006).
  • Varaut A, Fontaine H, Serpaggi J et al. Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation80(11), 1550–1555 (2005).
  • Poynard T, Morra R, Halfon P et al. Meta-analyses of Fibrotest diagnostic value in chronic liver disease. BMC Gastroenterol.7(1), 40 (2007).
  • Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology36(4 Pt 1), 986–992 (2002).
  • Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology38(2), 518–526 (2003).
  • Lok AS, Ghany MG, Goodman ZD et al. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology42(2), 282–292 (2005).
  • Patel K, Gordon SC, Jacobson I et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J. Hepatol.41(6), 935–942 (2004).
  • Leroy V, Monier F, Bottari S et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am. J. Gastroenterol.99(2), 271–279 (2004).
  • Rosenberg WM, Voelker M, Thiel R et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology127(6), 1704–1713 (2004).
  • Sud A, Hui JM, Farrell GC et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology39(5), 1239–1247 (2004).
  • Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand. J. Gastroenterol.40(7), 867–872 (2005).
  • Adams LA, Bulsara M, Rossi E et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin. Chem.51(10), 1867–1873 (2005).
  • Fontana RJ, Kleiner DE, Bilonick R et al. Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology44(4), 925–935 (2006).
  • Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology45(2), 297–306 (2007).
  • Hui AY, Chan HL, Wong VW et al. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am. J. Gastroenterol.100(3), 616–623 (2005).
  • Zeng MD, Lu LG, Mao YM et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology42(6), 1437–1445 (2005).
  • Kelleher TB, Mehta SH, Bhaskar R et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J. Hepatol.43(1), 78–84 (2005).
  • Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology43(6), 1317–1325 (2006).
  • Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology45(4), 846–854 (2007).
  • Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J. Hepatol.44(3), 462–474 (2006).
  • Sebastiani G, Vario A, Guido M et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J. Hepatol.44(4), 686–693 (2006).
  • Bourliere M, Penaranda G, Renou C et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J. Viral Hepatol.13(10), 659–670 (2006).
  • Fraser JR, Gibson PR. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans. J. Intern. Med.258(5), 460–466 (2005).
  • Piton A, Poynard T, Imbert-Bismut F et al. Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology27(5), 1213–1219 (1998).
  • Poynard T, Munteanu M, Imbert-Bismut F et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin. Chem.10, 10 (2004).
  • Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med. Biol.29(12), 1705–1713 (2003).
  • Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J. Hepatol.48(4), 606–613 (2008).
  • Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J. Hepatol.48(5), 835–847 (2008).
  • Ziol M, Handra-Luca A, Kettaneh A et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology41(1), 48–54 (2005).
  • Fraquelli M, Rigamonti C, Casazza G et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut56(7), 968–973 (2007).
  • Gomez-Dominguez E, Mendoza J, Rubio S, Moreno-Monteagudo JA, Garcia-Buey L, Moreno-Otero R. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment. Pharmacol. Ther.24(3), 513–518 (2006).
  • Ganne-Carrie N, Ziol M, de Ledinghen V et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology44(6), 1511–1517 (2006).
  • Foucher J, Chanteloup E, Vergniol J et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut55(3), 403–408 (2006).
  • Marcellin P, De Ledinghen V, Dhumeaux D et al. Non invasive assessment of liver fibrosis in chronic hepatitis B using FibroScan (abstract). Hepatology42(Suppl. 1), 715A (2005).
  • Coco B, Oliveri F, Maina AM et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J. Viral Hepatol.14(5), 360–369 (2007).
  • de Ledinghen V, Douvin C, Kettaneh A et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J. Acquir. Immune Defic. Syndr.41(2), 175–179 (2006).
  • Vergara S, Macias J, Rivero A et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin. Infect. Dis.45(8), 969–974 (2007).
  • Corpechot C, El Naggar A, Poujol-Robert A et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology43(5), 1118–1124 (2006).
  • Yoneda M, Fujita K, Inamori M, Nakajima A, Tamano M, Hiraishi H. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut56(9), 1330–1331 (2007).
  • Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl.12(12), 1791–1798 (2006).
  • Rigamonti C, Donato MF, Fraquelli M et al. Transient elastography predicts fibrosis progression in patients with recurrent hepatitis c after liver transplantation. Gut57(6), 821–827 (2008).
  • Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin. Gastroenterol. Hepatol.5(10), 1214–1220 (2007).
  • Poynard T, Halfon P, Castera L et al. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin. Chem.53(9), 1615–1622 (2007).
  • Kazemi F, Kettaneh A, N’Kontchou G et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J. Hepatol.45(2), 230–235 (2006).
  • Vizzutti F, Arena U, Romanelli RG et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology45(5), 1290–1297 (2007).
  • Castera L, Bernard PH, Le Bail B et al. What is the best non invasive method for early prediction of cirrhosis in chronic hepatitis C? Prospective comparison between Fibroscan and serum markers (Lok index, APRI, AST/ALT ratio, platelet count and Fibrotest) (abstract). Hepatology46(Suppl. 1), 156A (2007).
  • Pinzani M. Non-invasive evaluation of hepatic fibrosis: don’t count your chickens before they’re hatched. Gut55(3), 310–312 (2006).
  • Foucher J, Castera L, Bernard PH et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J. Gastroenterol. Hepatol.18(4), 411–412 (2006).
  • Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology47(2), 592–595 (2007).
  • Arena U, Vizzutti F, Corti G et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology47(2), 380–384 (2008).
  • Castera L, Foucher J, Bertet J, Couzigou P, de Ledinghen V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology43(2), 373–374 (2006).
  • Colletta C, Smirne C, Fabris C et al. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology42(4), 838–845 (2005).
  • Moreno-Otero R, Trapero-Marugan M, Mendoza J. Liver fibrosis assessment by transient elastography in hepatitis C patients with normal alanine aminotransferase. Gut55(7), 1055–1056 (2006).
  • Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection – analysis of 300 cases. Radiology227(1), 89–94 (2003).
  • Lim AK, Patel N, Eckersley RJ et al. Can Doppler sonography grade the severity of hepatitis C-related liver disease? AJR Am. J. Roentgenol.184(6), 1848–1853 (2005).
  • Aube C, Winkfield B, Oberti F et al. New Doppler ultrasound signs improve the non-invasive diagnosis of cirrhosis or severe liver fibrosis. Eur. J. Gastroenterol. Hepatol.16(8), 743–751 (2004).
  • Lim AK, Taylor-Robinson SD, Patel N et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut54(1), 128–133 (2005).
  • Talwalkar JA, Yin M, Fidler JL, Sanderson SO, Kamath PS, Ehman RL. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology47(1), 332–342 (2008).
  • Huwart L, Sempoux C, Salameh N et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology245(2), 458–466 (2007).
  • Yin M, Talwalkar JA, Glaser KJ et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin. Gastroenterol. Hepatol.5(10), 1207–1213 (2007).
  • Friedrich-Rust M, Ong MF, Herrmann E et al. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am. J. Roentgenol.188(3), 758–764 (2007).
  • Lewin M, Poujol-Robert A, Boelle PY et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology46(3), 658–665 (2007).
  • Castera L, Denis J, Babany G, Roudot-Thoraval F. Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: time for new guidelines? J. Hepatol.46(3), 528–529 (2007).
  • Poynard T, Imbert-Bismut F, Ratziu V et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J. Viral Hepatol.9(2), 128–133 (2002).
  • Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon α-2b and ribavirin. Hepatology38(2), 481–492 (2003).
  • Hézode C, Castéra L, Rosa I et al. Dynamics of liver stiffness during peginterferon α-ribavirin treatment in patients with chronic hepatitis C (abstract). Hepatology46(Suppl. 1), 366A (2007).
  • Takeda T, Yasuda T, Nakayama Y et al. Usefulness of noninvasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C. World J. Gastroenterol.12(48), 7768–7773 (2006).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.